The historical rank and industry rank for Shandong Boan Biotechnology Co's Net Margin % or its related term are showing as below:
FRA:UJ9'
s Net Margin % Range Over the Past 10 Years
Min: -142.04 Med: -19.31 Max: 10.08
Current: 0.89
FRA:UJ9's Net Margin % is ranked better than 72.03% of 944
companies
in the Biotechnology industry
Industry Median: -88.815
vs FRA:UJ9: 0.89
Shandong Boan Biotechnology Co (FRA:UJ9) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Shandong Boan Biotechnology Co Net Margin % Related Terms
Shandong Boan Biotechnology Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UJ9 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Shandong Boan Biotechnology Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Boan Biotechnology Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Shandong Boan Biotechnology Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co (FRA:UJ9) has a Net Margin % of -3.42% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Shandong Boan Biotechnology Co and its competitors. According to the industry distribution chart, Shandong Boan Biotechnology Co ranks #264 out of 944 companies in the Biotechnology industry, placing it in the top 28%.
Is Shandong Boan Biotechnology Co's Net Margin % too high?
Shandong Boan Biotechnology Co's current Net Margin % is -3.42%. Based on the distribution chart, Shandong Boan Biotechnology Co ranks #264 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shandong Boan Biotechnology Co ranks #264 out of 944 companies for Net Margin %. This puts Shandong Boan Biotechnology Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Shandong Boan Biotechnology Co and its competitors. Shandong Boan Biotechnology Co's current Net Margin % is -3.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current Net Margin % of -3.42%. The stock's GF Value™ is €1.69, compared to a current price of €0.50 — trading 70.4% below its estimated fair value. The current Net Margin % is -3.42%. Shandong Boan Biotechnology Co's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current Net Margin % is -3.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued.
The current stock price of €0.50 is trading 70.4% below its estimated GF Value™ of €1.69.
Key valuation signals for FRA:UJ9:
Net Margin %: -3.42%
GF Value™: €1.69 vs. price of €0.50 (70.4% below fair value)
No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Boan Biotechnology Co Business Description
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score
Get the complete analysis for FRA:UJ9
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UJ9 has been successfully added to your 
